China Medical System Holdings Limited
CHSYF
Other OTC1.57
USD
- -
- -
ISIN
KYG211081248
CUSIP
G21108124
Return %
Stock
S&P500
1Y
3.29
19.25
3Y
3.29
65.11
5Y
-34.58
72.21
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kong Lam
- Full Time Employees
- 6,415
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Island Place Tower North Point GD Hong Kong
- IPO Date
- Apr 5, 2013
- Website
- cms.net.cn
- Similar Companies
- Business
- China Medical System Holdings Limited (CMS) is an investment holding company engaged in the marketing, promotion, sales, and production of pharmaceutical products, with a focus on linking pharmaceutical innovation and commercialization through strong product lifecycle management capabilities. The company offers a portfolio of marketed products spanning cardio-cerebrovascular and gastroenterology (including Plendil, Ursofalk, Salofalk, Imdur, and XinHuoSu); ophthalmology (including Augentropfen Stulln Mono Eye Drops, Lucentis, and Beovu); dermatology (including Hirudoid, Atopic Piel Series, and ruxolitinib cream); and medical aesthetics (including Vmonalisa), alongside innovative biologics and devices targeting unmet clinical needs in chronic and life-threatening diseases. CMS operates a mature commercialization platform compliant with international standards, featuring professional promotion teams, extensive channel resources, and expert networks, primarily serving hospitals, distributors, and wholesale customers. In recent developments, CMS filed for and completed a secondary listing on the Singapore Exchange mainboard in July 2025 under ticker 8A8.SG to expand its presence in Southeast Asia's pharmaceutical market, establishing CMS R&D in Singapore in 2024 for over 10 early-stage innovative drug projects. The company entered exclusive collaboration agreements in September 2025 with Chongqing Genrix Biopharmaceutical for innovative biologics Vecantoxatug and Silevimig injections used for passive immunization against tetanus; a distribution agreement in October 2025 with Novartis Pharma Services AG for ophthalmic drugs Ranibizumab (Lucentis) and Brolucizumab (Beovu) injections; and a January 2025 co-development and commercialization deal with Mabgeek Biotech for Class 1 innovative drug MG-K10, a long-acting anti-IL-4Rα monoclonal antibody for atopic dermatitis that achieved positive Phase III results. Additional milestones include NMPA acceptance of the new drug application for ZUNVEYL (benzgalantamine) for Alzheimer's disease in July 2025, regulatory approvals for clinical trials of povorcitinib (Jak1 inhibitor), CMS-D002 (GnRH antagonist for uterine fibroids), and other pipeline assets, contributing to H1 2025 revenue and profit growth amid strategic transformation. Founded in 1995 and incorporated in the Cayman Islands in 2006, CMS is headquartered at Unit 2106, 21/F, Island Place Tower, 510 King's Road, North Point, Hong Kong, and is a subsidiary of Treasure Sea Limited. The company primarily operates in Mainland China, with expanding activities in Hong Kong, Macau, Taiwan, Singapore, and broader Southeast Asia markets serving nearly 700 million people, supported by approximately 6,100 employees and a pipeline of about 40 differentiated innovative products, including 20 in-house R&D projects. CMS maintains leading academic and market positions in its specialty therapeutic areas through deep clinical insights, government affairs expertise, and a patient-centered approach.
China Medical System (CHSYF) to Release Quarterly Earnings on Monday